CA
NZ
UK
AU
IND
US
● The net loss widened to US$120.4 million from US$82.5 million.
● Aardvark terminated the Phase 3 HERO trial and its extension in June.
● The charge reduces earnings by $0.11 per diluted share.
● Daily hot flashes fell by 8.8 events with ABCL635 versus 3.5 with placebo.
● Five patients were treated in the quarter, with revenue recognised for four.
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Capricor announced on August 24 that the FDA extended the PDUFA date for deramiocel, a cell therapy for Duchenne muscular …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. C4 Therapeutics develops targeted protein degraders, and its lead drug cemsidomide is an oral molecular glue degrader of IKZF1 and …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. LENZ Therapeutics sells VIZZ, the first aceclidine eye drop for presbyopia, and reported second-quarter 2026 revenue of USD 5.5 million, …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Intellia Therapeutics, a CRISPR gene editing company, fell 4.97% to USD 11.95 on volume of 13.954 million shares, about 3.4 …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Novavax reported second-quarter 2026 total revenue of USD 57 million, down 76% from USD 239 million a year earlier, when …
Please wait processing your request...